Form 4: Stepan Co. Grants Equity Awards to VP Shawn Lisle

Stepan Company's VP, General Counsel, and Secretary, Shawn G. Lisle, received grants of restricted stock units, performance shares, and stock appreciation rights.

Summary

• Shawn G. Lisle, VP GC & Secretary of Stepan Company (SCL), was granted equity awards on August 26, 2025.
• The awards include 3,462 Restricted Stock Units (RSUs), 1,731 Performance Shares, and 4,861 Stock Appreciation Rights (SARs).
• Each RSU and Performance Share represents a contingent right to receive one share of Stepan Company common stock.
• The SARs have an exercise price of $50.55.

Sentiment

Score: 5

Explanation: The filing reports a routine grant of equity compensation to a senior executive, which is a standard practice for publicly traded companies. It is neither overwhelmingly positive nor negative, representing an expected part of executive incentive structures.

Positives

• The grant of equity awards aligns the interests of Shawn G. Lisle with those of shareholders, incentivizing long-term performance.
• Performance shares are tied to specific company performance goals, encouraging the achievement of strategic objectives.

Negatives

• The issuance of new equity awards could lead to potential future dilution for existing shareholders when units vest and convert to common stock.

Risks

• Achievement of performance goals for the performance shares is uncertain, meaning the full value of these awards may not be realized.
• The value of the Stock Appreciation Rights is dependent on the future stock price exceeding the exercise price of $50.55.

Future Outlook

The vesting of performance shares is contingent on Stepan Company achieving certain performance goals by December 31, 2027, indicating a focus on future operational and financial targets.

Industry Context

Executive equity compensation, including RSUs, performance shares, and SARs, is a standard practice across many industries to attract, retain, and incentivize key management personnel, aligning their interests with long-term shareholder value creation.

Comparison to Industry Standards

• The use of a mix of time-based (RSUs) and performance-based (Performance Shares, SARs) equity awards is a common practice in executive compensation packages across publicly traded companies, including those in the specialty chemicals sector like Stepan Company.
• The vesting schedules (ratable over three years for RSUs/SARs, performance-based for Performance Shares) are typical for long-term incentive plans designed to retain executives and reward sustained performance.
• The specific exercise price for SARs ($50.55) would need to be compared to the company's stock price on the grant date to assess its immediate 'in-the-money' or 'out-of-the-money' status, which is standard practice.

Related Party Transactions

• The grant of equity awards to Shawn G. Lisle, an officer of Stepan Company, constitutes a related party transaction as it involves compensation provided by the company to a key management personnel.

Stakeholder Impact

• Shareholders: Potential future dilution from the conversion of RSUs and performance shares into common stock. However, the awards are designed to align management interests with shareholder value creation.
• Employees: No direct impact on general employees, but it reflects the company's executive compensation strategy.
• Management: Shawn G. Lisle receives long-term incentives, aligning his financial interests with the company's performance.

Next Steps

• Shawn G. Lisle's Restricted Stock Units and Stock Appreciation Rights will begin vesting ratably over three years starting August 26, 2026.
• The Performance Shares will vest upon the certification of Stepan Company achieving specific performance goals for the period ending December 31, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a senior executive. While it aligns management incentives with shareholder interests, it does not present new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in an investment recommendation. It is an expected part of executive compensation.

Keywords

Stepan Company, SCL, Shawn G. Lisle, Form 4, Restricted Stock Units, Performance Shares, Stock Appreciation Rights, Equity Grant, Executive Compensation, Insider Transaction